Soligenix has scrapped its cutaneous T-cell lymphoma program in the wake of a phase 3 setback, leaving the biotech focused on another rare disease prospect and considering strategic alternatives.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Soligenix has scrapped its cutaneous T-cell lymphoma program in the wake of a phase 3 setback, leaving the biotech focused on another rare disease prospect and considering strategic alternatives.